Prescription Opioid Misuse Assessment

Summary

Chronic pain is a worldwide health problem due to its high prevalence and its difficult management with a significant impact on quality of life. Pain and addiction co-occur frequently. Indeed, the prevalence of addiction in patients with chronic non-cancer pain may affect from 0% to 50% of patients (Højsted et al 2010). This large variability in the estimation of addiction prevalence in chronic non-cancer pain patients is at least partly due to a lack of standardization of the selected patients from the clinical or therapeutic point of view and the lack of consensus in the use of a specific evaluation tool or gold standard. Indeed, several tools are currently available at the international level with varying efficiencies and precisions (Chou et al 2009, Turk, Swanson, and Gatchel 2008, Højsted and Sjøgren 2007). In France, no data are available on the prevalence of analgesic opioid misuse in chronic non-cancer pain patients, due to the lack clinical studies and validated tools in French.

Conditions

• Chronic Pain

Interventions

OTHER

Prescription Opioid Misus Index

Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.

Sponsors & Collaborators

• CEIP-A Lyon

  collaborator UNKNOWN

• CEIP-A Marseille

  collaborator UNKNOWN

• CEIP-A Caen

  collaborator UNKNOWN

• CEIP-A Lille

  collaborator UNKNOWN

• CEIP-A Montpellier

  collaborator UNKNOWN

• CEIP-A Nantes

  collaborator UNKNOWN

• CEIP-A Poitiers

  collaborator UNKNOWN

• CEIP-A Toulouse

  collaborator UNKNOWN

• CEIP-A Bordeaux

  collaborator UNKNOWN

• University Hospital, Clermont-Ferrand

  lead OTHER

Principal Investigators

• Nicolas AUTHIER · CHU de Clermont-Ferrand

Eligibility

Min Age

18 Years

Max Age

100 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-08-24

Primary Completion

2019-07-09

Completion

2019-07-30

Countries

• France

Study Locations